文献速递垂体与肾上腺疾病

放疗尤其是年轻时放疗增加垂体/蝶鞍区病变患者新发脑肿瘤风险

Radiotherapy, Especially at Young Age, Increases the Risk for De Novo Brain Tumors in Patients Treated for Pituitary/Sellar Lesions.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

基于KIMS数据库1994至2012年8917例垂体/蝶鞍区病变所致垂体功能减退患者,比较放疗与未放疗者新发恶性脑肿瘤和脑膜瘤的发生率。放疗组恶性脑肿瘤风险比为3.34(95%CI 1.06-10.6),脑膜瘤为4.06(95%CI 1.51-10.9);放疗时年龄每年轻10岁,恶性脑肿瘤风险增加2.4倍(P=0.005),脑膜瘤增加1.6倍(P=0.05)。作者认为放疗与风险增加相关,尤其年轻时放疗,权衡利弊时应特别考虑患者年龄。

要点

  • 放疗与恶性脑肿瘤风险增加相关,风险比(RR)为3.34(95%CI 1.06-10.6)。
  • 放疗与脑膜瘤风险增加相关,RR为4.06(95%CI 1.51-10.9)。
  • 放疗时年龄每年轻10岁,恶性脑肿瘤风险增加2.4倍(P=0.005),脑膜瘤增加1.6倍(P=0.05)。

核心结论

  • 垂体肿瘤放疗与恶性脑肿瘤和脑膜瘤风险增加相关,尤其在年轻时放疗时。
  • 作者认为在权衡放疗利弊时,应特别考虑患者年龄。

研究设计与样本

  • 纳入KIMS(辉瑞国际代谢数据库)1994至2012年随访的8917例因垂体腺瘤、颅咽管瘤及其他蝶鞍肿瘤所致垂体功能减退患者。
  • 治疗为手术和/或药物治疗者4927例,放疗单独或联合手术者3236例,数据缺失754例。
  • 采用泊松回归方法进行内部比较分析发生率比(RR)。

主要发现

  • 共随访53786患者年,报告恶性脑肿瘤17例(其中13例暴露于放疗)和脑膜瘤27例(其中22例暴露于放疗)。
  • 放疗 vs 未放疗的RR:恶性脑肿瘤为3.34(95%CI 1.06-10.6),脑膜瘤为4.06(95%CI 1.51-10.9)。
  • 放疗时年龄每年轻10岁,恶性脑肿瘤风险增加2.4倍(P=0.005),脑膜瘤风险增加1.6倍(P=0.05)。
  • 常规放疗与立体定向放疗患者的发生率相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: De novo brain tumors developing after treatment of pituitary/sellar lesions have been reported, but it is unknown whether this is linked to any of the treatment modalities. OBJECTIVE: To study the occurrence of malignant brain tumors and meningiomas in a large cohort of patients treated for pituitary/sellar lesions, with special emphasis on the role of radiotherapy (RT). PATIENTS AND METHODS: Patients (n = 8917) who were hypopituitary due to pituitary adenomas, craniopharyngiomas, and other sellar tumors followed in KIMS (Pfizer International Metabolic Database) from 1994 to 2012 were included. Treatment consisted of surgery and/or medical therapy in 4927 patients, RT alone, or with surgery in 3236 patients; data were missing in 754. Incidence rate ratios (RRs) were analyzed through Poisson regression methods with internal comparisons. RESULTS: During 53,786 patient-years, 17 cases of malignant brain tumors (13 exposed to RT) and 27 meningiomas (22 exposed to RT) were reported. RR for RT vs no RT was 3.34 [95% confidence interval (CI), 1.06 to 10.6] for malignant brain tumors, and 4.06 (95% CI, 1.51 to 10.9) for meningiomas. The risk of developing a malignant brain tumor increased by 2.4-fold (P = 0.005) and meningioma by 1.6-fold with every 10 years of younger age at RT (P = 0.05). Incidence rates were similar in patients treated with conventional RT compared with stereotactic RT. CONCLUSION: RT of pituitary tumors is associated with increased risk of developing malignant brain tumors and meningiomas, especially when given at younger ages. In balancing risks and benefits of RT, our findings emphasize that special consideration should be given to the age of the patient.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Burman P, van Beek AP, Biller BM, et al. Radiotherapy, Especially at Young Age, Increases the Risk for De Novo Brain Tumors in Patients Treated for Pituitary/Sellar Lesions. J Clin Endocrinol Metab. 2017. PMID: 28359095. doi:10.1210/jc.2016-3402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。